BR112017020941A2 - imidazolonilquinolinas e seu uso como inibidores da atm cinase - Google Patents

imidazolonilquinolinas e seu uso como inibidores da atm cinase

Info

Publication number
BR112017020941A2
BR112017020941A2 BR112017020941-1A BR112017020941A BR112017020941A2 BR 112017020941 A2 BR112017020941 A2 BR 112017020941A2 BR 112017020941 A BR112017020941 A BR 112017020941A BR 112017020941 A2 BR112017020941 A2 BR 112017020941A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
imidazolonylquinolines
atm kinase
atm
het1
Prior art date
Application number
BR112017020941-1A
Other languages
English (en)
Other versions
BR112017020941B1 (pt
Inventor
Fuchss Thomas
Schiemann Kai
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to BR122019005502-5A priority Critical patent/BR122019005502B1/pt
Publication of BR112017020941A2 publication Critical patent/BR112017020941A2/pt
Publication of BR112017020941B1 publication Critical patent/BR112017020941B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

compostos da fórmula (i), em que r1, r3, het1 e het possuem os significados dados de acordo com a reivindicação 1, são inibidores da atm cinase e podem ser empregados, inter alia, para o tratamento de câncer.
BR112017020941-1A 2015-04-02 2016-03-31 Imidazolonilquinolinas, seus usos, composições farmacêuticas, e kit BR112017020941B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019005502-5A BR122019005502B1 (pt) 2015-04-02 2016-03-31 Compostos de imidazolonilquinolinas, seus usos, composições farmacêuticas, e kit

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15000968 2015-04-02
EP15000968.6 2015-04-02
PCT/EP2016/000542 WO2016155884A1 (de) 2015-04-02 2016-03-31 Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren

Publications (2)

Publication Number Publication Date
BR112017020941A2 true BR112017020941A2 (pt) 2018-07-10
BR112017020941B1 BR112017020941B1 (pt) 2023-09-12

Family

ID=

Also Published As

Publication number Publication date
HRP20191396T1 (hr) 2019-11-01
IL271494B (en) 2021-05-31
DK3560924T3 (da) 2021-06-28
CN111747952A (zh) 2020-10-09
ES2880626T3 (es) 2021-11-25
EP3560924A1 (de) 2019-10-30
CA2981365A1 (en) 2016-10-06
AU2020204241B2 (en) 2022-11-17
TR201911244T4 (tr) 2019-08-21
US10975075B2 (en) 2021-04-13
JP7111790B2 (ja) 2022-08-02
SI3277681T1 (sl) 2019-09-30
JP2021046403A (ja) 2021-03-25
EP3868761B1 (de) 2023-03-01
AU2020204241A1 (en) 2020-07-16
EP3277681A1 (de) 2018-02-07
ES2946507T3 (es) 2023-07-20
SI3560924T1 (sl) 2021-08-31
BR122019005502B1 (pt) 2024-02-27
RU2743343C2 (ru) 2021-02-17
AU2022256215A1 (en) 2022-11-24
IL282584B (en) 2021-12-01
US20190211013A1 (en) 2019-07-11
LT3560924T (lt) 2021-08-25
EP3560924B1 (de) 2021-03-31
US10457677B2 (en) 2019-10-29
DK3277681T3 (da) 2019-07-29
SG10202002181UA (en) 2020-05-28
IL254714A0 (en) 2017-11-30
EP3277681B1 (de) 2019-05-08
HUE054745T2 (hu) 2021-09-28
US20230203034A1 (en) 2023-06-29
ES2741853T3 (es) 2020-02-12
EP3868761A1 (de) 2021-08-25
RU2017138100A3 (pt) 2019-10-04
IL254714B (en) 2020-01-30
KR102652052B1 (ko) 2024-03-27
JP6791873B2 (ja) 2020-11-25
MX2020011558A (es) 2022-03-09
RS62082B1 (sr) 2021-08-31
US20200325137A1 (en) 2020-10-15
PL3560924T3 (pl) 2021-10-11
PT3277681T (pt) 2019-08-20
KR20240044525A (ko) 2024-04-04
SG11201708065QA (en) 2017-10-30
AU2016239270B2 (en) 2020-03-26
ZA201707423B (en) 2021-05-26
MX2017012613A (es) 2018-01-24
US10745399B2 (en) 2020-08-18
LT3277681T (lt) 2019-08-12
PL3277681T3 (pl) 2019-10-31
US11608338B2 (en) 2023-03-21
KR20170132323A (ko) 2017-12-01
HUE045477T2 (hu) 2019-12-30
AU2016239270A1 (en) 2017-11-16
HRP20210981T1 (hr) 2021-09-17
US20210198257A1 (en) 2021-07-01
IL271494A (en) 2020-02-27
WO2016155884A1 (de) 2016-10-06
RU2017138100A (ru) 2019-05-08
JP2018510191A (ja) 2018-04-12
US20180072715A1 (en) 2018-03-15
CN111689963A (zh) 2020-09-22
IL282584A (en) 2021-06-30
PT3560924T (pt) 2021-07-02
RS59139B1 (sr) 2019-09-30
CN107889488B (zh) 2020-08-11
CN107889488A (zh) 2018-04-06

Similar Documents

Publication Publication Date Title
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
SV2017005471A (es) Derivados de quinazolina utilizados para tratar el vih
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
BR112015025413A2 (pt) inibidores de proteína cinase
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CR20160229A (es) Inhibidires de bromodominio
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
BR112018013977A2 (pt) derivados de quinolin-2-ona
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2016, OBSERVADAS AS CONDICOES LEGAIS